See more : Sungmoon Electronics Co., Ltd. (014915.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Apyx Medical Corporation (APYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apyx Medical Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Pasithea Therapeutics Corp. (KTTA) Income Statement Analysis – Financial Results
- Wonik Pne Co., Ltd. (217820.KQ) Income Statement Analysis – Financial Results
- Fangda Special Steel Technology Co., Ltd. (600507.SS) Income Statement Analysis – Financial Results
- Alkame Holdings, Inc. (ALKM) Income Statement Analysis – Financial Results
- HighCom Global Security, Inc. (HCGS) Income Statement Analysis – Financial Results
Apyx Medical Corporation (APYX)
About Apyx Medical Corporation
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.35M | 44.51M | 48.52M | 27.71M | 28.15M | 16.69M | 38.88M | 36.63M | 29.52M | 27.68M | 23.66M | 27.67M | 25.41M | 24.23M | 26.95M | 28.10M | 28.78M | 26.68M | 20.21M | 20.50M | 16.55M | 12.45M | 11.48M | 9.94M | 9.60M | 8.44M | 7.37M | 7.49M | 5.52M |
| Cost of Revenue | 18.59M | 15.38M | 14.92M | 10.21M | 9.03M | 5.89M | 19.12M | 18.71M | 16.96M | 18.69M | 14.46M | 16.34M | 14.68M | 14.24M | 15.10M | 16.25M | 17.46M | 16.08M | 12.65M | 12.51M | 9.43M | 7.19M | 5.72M | 4.60M | 4.59M | 5.27M | 4.14M | 4.13M | 3.22M |
| Gross Profit | 33.76M | 29.13M | 33.60M | 17.50M | 19.13M | 10.79M | 19.76M | 17.92M | 12.56M | 8.99M | 9.20M | 11.33M | 10.73M | 9.99M | 11.85M | 11.85M | 11.32M | 10.60M | 7.56M | 7.98M | 7.12M | 5.26M | 5.76M | 5.34M | 5.01M | 3.17M | 3.23M | 3.35M | 2.31M |
| Gross Profit Ratio | 64.49% | 65.45% | 69.26% | 63.17% | 67.94% | 64.68% | 50.82% | 48.91% | 42.54% | 32.48% | 38.88% | 40.96% | 42.23% | 41.22% | 43.98% | 42.17% | 39.32% | 39.74% | 37.41% | 38.94% | 43.00% | 42.23% | 50.15% | 53.74% | 52.19% | 37.53% | 43.85% | 44.77% | 41.76% |
| Research & Development | 4.84M | 4.54M | 4.32M | 3.92M | 3.81M | 2.47M | 2.46M | 2.62M | 2.16M | 1.42M | 1.26M | 1.33M | 1.20M | 1.85M | 2.08M | 2.06M | 1.64M | 1.19M | 985.81K | 907.39K | 717.35K | 693.71K | 463.13K | 513.02K | 379.83K | 183.17K | 96.74K | 105.70K | 121.90K |
| General & Administrative | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 2.30M | 1.30M | 800.00K | 1.50M | 800.00K | 11.37M | 8.57M | 8.42M | 6.69M | 4.89M | 4.34M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.87M | 48.15M | 43.73M | 33.67M | 36.23M | 21.18M | 21.05M | 19.09M | 17.38M | 13.43M | 9.96M | 8.96M | 10.30M | 9.60M | 9.06M | 8.50M | 7.57M | 6.79M | 6.01M | 5.76M | 5.60M | 4.91M | 4.71M | 3.90M | 6.46M | 1.75M | 0.00 | 1.34M | 1.18M |
| Other Expenses | 0.00 | 509.00K | -373.00K | 479.00K | -382.00K | -203.00K | -11.37M | -8.57M | -8.42M | -6.69M | -4.89M | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 161.19K | 39.29K | 81.91K | 124.45K | 0.00 | 396.81K | 321.17K | 2.15M | 2.80M | 1.43M | 1.22M |
| Operating Expenses | 51.02M | 52.69M | 48.05M | 37.59M | 40.04M | 23.65M | 23.50M | 21.71M | 19.54M | 14.84M | 11.22M | 10.29M | 11.50M | 11.45M | 11.14M | 10.56M | 9.21M | 7.98M | 7.16M | 6.70M | 6.40M | 5.73M | 5.18M | 4.81M | 7.16M | 4.09M | 2.89M | 2.87M | 2.53M |
| Cost & Expenses | 69.61M | 68.07M | 62.97M | 47.79M | 49.07M | 29.55M | 42.62M | 40.42M | 36.51M | 33.53M | 25.69M | 26.63M | 26.18M | 25.70M | 26.24M | 26.81M | 26.67M | 24.05M | 19.81M | 19.22M | 15.84M | 12.92M | 10.90M | 9.41M | 11.75M | 9.36M | 7.03M | 7.01M | 5.74M |
| Interest Income | 921.00K | 157.00K | 11.00K | 241.00K | 1.39M | 616.00K | 0.00 | 0.00 | 1.00K | 0.00 | 7.00K | 0.00 | 12.00K | 0.00 | 24.36K | 48.76K | 142.72K | 103.09K | 46.96K | 3.26K | 2.98K | 5.21K | 10.11K | 28.75K | 0.00 | 4.16K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.48M | 15.00K | 10.00K | 46.00K | 8.00K | 104.00K | 136.00K | 158.00K | 158.00K | 151.00K | 237.00K | 232.00K | 249.00K | 223.00K | 76.37K | 58.46K | 2.47K | 16.16K | 22.70K | 15.09K | 34.06K | 48.45K | 70.69K | 66.80K | 0.00 | 103.84K | 0.00 | 75.80K | 68.70K |
| Depreciation & Amortization | 692.00K | 890.00K | 903.00K | 887.00K | 754.00K | 669.00K | 696.00K | 734.00K | 812.00K | 876.00K | 827.00K | 857.00K | 925.00K | 1.01M | 1.05M | 973.07K | 770.83K | 529.26K | 545.88K | 395.12K | 314.68K | 274.88K | 524.24K | 396.81K | 321.17K | 787.09K | 311.14K | 260.60K | 171.00K |
| EBITDA | -18.11M | -22.01M | -13.91M | -18.48M | -19.07M | -13.92M | -13.01M | -3.79M | -4.37M | -12.25M | -3.68M | 1.93M | 1.19M | -1.23M | 1.79M | 3.81M | 2.88M | 3.15M | 949.84K | 1.67M | 978.14K | -199.02K | 1.16M | 926.71K | 947.21K | -133.07K | 650.72K | 741.00K | -48.50K |
| EBITDA Ratio | -34.60% | -51.44% | -30.53% | -69.87% | -70.69% | -78.28% | -9.62% | -10.35% | -23.67% | -21.13% | -10.17% | 6.88% | 3.62% | 1.29% | 6.64% | 2.74% | 10.00% | 11.82% | 4.70% | 8.17% | 6.70% | -0.62% | 9.21% | 9.24% | -19.07% | -1.83% | 8.36% | 9.75% | -1.92% |
| Operating Income | -17.26M | -23.56M | -14.45M | -20.08M | -20.91M | -13.60M | -5.27M | -3.79M | -6.99M | -5.85M | -3.67M | 1.05M | -18.00K | -2.75M | 714.85K | 1.29M | 2.11M | 2.62M | 403.97K | 1.28M | 712.40K | -473.90K | 583.58K | 529.90K | -2.15M | -920.16K | 339.58K | 480.40K | -219.50K |
| Operating Income Ratio | -32.97% | -52.94% | -29.78% | -72.47% | -74.28% | -81.51% | -13.54% | -10.35% | -23.67% | -21.13% | -15.49% | 3.78% | -0.07% | -11.36% | 2.65% | 4.60% | 7.32% | 9.84% | 2.00% | 6.24% | 4.30% | -3.81% | 5.08% | 5.33% | -22.38% | -10.90% | 4.61% | 6.42% | -3.98% |
| Total Other Income/Expenses | -4.02M | 651.00K | -372.00K | 674.00K | 1.03M | -1.09M | -8.57M | -94.00K | 1.64M | -7.44M | -2.29M | -212.00K | 50.00K | 290.00K | -52.01K | 1.49M | 140.25K | 86.93K | 24.26K | -11.83K | -31.08K | -40.87K | -431.47K | 8.79K | 3.25K | -77.88K | -240.39K | -64.80K | 65.40K |
| Income Before Tax | -21.28M | -22.91M | -14.82M | -19.41M | -19.91M | -13.27M | -5.22M | -3.89M | -5.35M | -13.29M | -5.95M | 834.00K | 32.00K | -2.46M | 662.84K | 2.78M | 2.25M | 2.71M | 428.22K | 1.27M | 681.32K | -514.77K | 200.59K | 538.69K | -2.14M | -998.05K | 99.19K | 415.60K | -154.10K |
| Income Before Tax Ratio | -40.65% | -51.47% | -30.55% | -70.04% | -70.72% | -79.53% | -13.42% | -10.61% | -18.11% | -47.99% | -25.16% | 3.01% | 0.13% | -10.16% | 2.46% | 9.88% | 7.81% | 10.16% | 2.12% | 6.18% | 4.12% | -4.14% | 1.75% | 5.42% | -22.35% | -11.82% | 1.35% | 5.55% | -2.79% |
| Income Tax Expense | -2.43M | 367.00K | 380.00K | -7.50M | -260.00K | -3.78M | -156.00K | 64.00K | 25.00K | 4.00M | -1.61M | 217.00K | -77.00K | -927.00K | 67.32K | 945.42K | -148.84K | 47.57K | 32.02K | -272.72K | 31.08K | 40.87K | -211.19K | 29.27K | 35.81K | 77.88K | 240.39K | 8.30K | -65.40K |
| Net Income | -18.71M | -23.28M | -15.20M | -11.91M | -19.65M | 64.01M | -5.06M | -3.95M | -5.37M | -17.28M | -4.34M | 617.00K | 109.00K | -1.54M | 595.52K | 1.83M | 2.40M | 2.68M | 406.21K | 1.51M | 681.32K | -514.77K | 784.29K | 500.63K | -2.18M | -998.05K | 99.19K | 407.30K | -154.10K |
| Net Income Ratio | -35.75% | -52.30% | -31.33% | -42.96% | -69.79% | 383.61% | -13.02% | -10.78% | -18.19% | -62.43% | -18.34% | 2.23% | 0.43% | -6.34% | 2.21% | 6.52% | 8.34% | 10.06% | 2.01% | 7.38% | 4.12% | -4.14% | 6.83% | 5.04% | -22.75% | -11.82% | 1.35% | 5.44% | -2.79% |
| EPS | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.93 | -0.16 | -0.14 | -0.22 | -0.98 | -0.25 | 0.04 | 0.01 | -0.09 | 0.04 | 0.11 | 0.15 | 0.19 | 0.03 | 0.11 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| EPS Diluted | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 | 1.86 | -0.16 | -0.14 | -0.19 | -0.97 | -0.25 | 0.03 | 0.01 | -0.09 | 0.03 | 0.11 | 0.13 | 0.16 | 0.03 | 0.09 | 0.05 | -0.04 | 0.06 | 0.04 | -0.16 | -0.07 | 0.01 | 0.05 | -0.04 |
| Weighted Avg Shares Out | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 33.19M | 31.42M | 27.43M | 24.33M | 17.68M | 17.49M | 17.63M | 17.60M | 17.37M | 16.90M | 16.07M | 15.32M | 14.54M | 13.92M | 13.75M | 13.63M | 13.20M | 13.45M | 13.90M | 13.88M | 13.88M | 8.19M | 7.66M | 4.35M |
| Weighted Avg Shares Out (Dil) | 34.62M | 34.52M | 34.33M | 34.21M | 34.07M | 34.37M | 31.43M | 27.45M | 27.75M | 17.76M | 17.67M | 17.79M | 17.67M | 17.37M | 17.84M | 17.09M | 17.68M | 16.91M | 15.75M | 16.80M | 13.63M | 14.41M | 14.76M | 16.07M | 13.88M | 13.88M | 8.44M | 7.66M | 4.35M |
APYX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 5, 2022 in the Class Action Filed on Behalf of Apyx Medical Corporation Shareholders
NEW YORK , Aug. 2, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) alleging that the Company violated federal securities laws. Class Period:...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Apyx Medical Corporation - APYX
NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX). Such investors are advised to contact Robert S.
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Apyx Investors of a Lead Plaintiff Deadline of August 5, 2022
NEW YORK , Aug. 1, 2022 /PRNewswire/ -- Attention Apyx Medical Corporation ("Apyx") (NASDAQ: APYX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between May 12, 2021...
APYX FINAL DEADLINE FRIDAY: ROSEN, A RESPECTED AND LEADING FIRM, Encourages Apyx Medical Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - APYX
New York, New York--(Newsfile Corp. - July 30, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both...
APYX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 5, 2022 in the Class Action Filed on Behalf of Apyx Medical Corporation Limited Shareholders
New York, New York--(Newsfile Corp. - July 29, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) alleging that the Company violated federal securities...
APYX FINAL DEADLINE AUGUST 5: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Apyx Medical Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - APYX
NEW YORK , July 29, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Apyx Medical Corporation (NASDAQ: APYX) between May 12, 2021 and March 11, 2022, both dates inclusive...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Apyx Medical Corporation with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - July 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ: APYX) for violations of §§10(b)...
APYX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apyx Medical Corporation
New York, New York--(Newsfile Corp. - July 28, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apyx Medical Corporation ("Apyx") (NASDAQ: APYX) between May...
APYX最后期限提醒：全球顶尖律所ROSEN鼓励Apyx Medical Corporation投资者在APYX证券集体诉讼的重要截止日期8月5日之前聘请律师
纽约--(BUSINESS WIRE)--(美国商业资讯)--原因：全球投资者权益律师事务所Rosen Law Firm提醒在2021年5月12日至2022年3月11日期间（含上述日期，简称“集体诉讼期”）购买Apyx Medical Corporation (NASDAQ: APYX)证券的人士牢记，首席原告的截止日期为2022年8月5日。 这意味着什么：在集体诉讼期购买了Apyx证券的人士，可以通过风险代理费安排，有机会无需支付任何自付费用和花销而获得赔偿。 接下来该如何做：如需加入Apyx集体诉讼，请访问https://rosenlegal.com/submit-form/?case_id=6835、拨打免费电话866-767-3653或者发送电子邮件至[email protected]或[email protected]联系Phillip Kim律师，了解有关集体诉讼的更多信息。律所已经提起了集体诉讼案。如果您希望担任首席原告，则必须在2022年8月5日之前向法院提出申请。首席原告是代表其他集体成员主导诉讼的代表方。 为什么选择ROSEN LAW：我们鼓励投资者选择有资质且在担任领导职务方面有着成功可查记录的律师。通常，发布通知的律所并无可相比的经验、资源或任何严谨的同行认可。许多此类律所实际上并不从事证券集体诉讼，只是充当中间人，将客户介绍给真正提起诉讼的律所，或与真正提起诉讼的律所合作。请务必明智选择法律顾问。Rosen Law Firm在全球范围内为投资者提供服务，专注于证券集体诉讼和股东派生诉讼。Rosen Law Firm曾针对一家中国公司发起了迄今规模最大的证券集体诉讼，并成功达成了和解。Rosen Law Firm曾因其证券集体诉讼和解数量，于2017年被ISS Securities Class Action Services评选为排名第一的律所。自2013年以来，Rosen Law Firm每年都进入了该榜单的前四强，而且为投资者追回了数亿美元的资金。律所仅在2019年便为投资者追回了超过4.38亿美元的资金。2020年，创始合伙人Laurence Rosen被law360评选为“最佳原告律师”(Titan of Plaintiffs’ Bar)。律所的众多律师都得到了Lawdragon和Super Lawyers的表彰。 案件详情：本诉讼认为，被告在整个集体诉讼期间作出了虚假和/或误导性陈述，和/或未披露：(1)大量Apyx的Advanced Energy产品被用于说明书之外的适应症；(2)此类未按说明书使用行为导致Apyx提交的报告严重不良事件的医疗器械报告数量增加；(3)因此，Apyx很可能受到监管部门审查；(4)由于上述原因，Apyx的财务业绩将受到不利影响；以及(5)由于上述原因，被告关于Apyx的业务、经营和前景的积极陈述具有重大误导性和/或缺乏合理依据。诉讼称，当市场了解真实情况后，投资者便蒙受了损失。 如需加入Apyx集体诉讼，请访问https://rosenlegal.com/submit-form/?case_id=6835、拨打免费电话866-767-3653或者发送电子邮件至[email protected]或[email protected]联系Phillip Kim律师，了解有关集体诉讼的更多信息。 上述诉讼的集体尚未得到认证。在此之前，除受聘之外，律师将不会为个人提供法律服务。个人可自行选择聘请律师，也可以作为缺席集体诉讼成员，且目前无需采取任何行动。投资者在未来任何可能的赔偿中的分成金额大小与其是否作为首席原告无关。 敬请通过LinkedIn：https://www.linkedin.com/company/the-rosen-law-firm、Twitter：https://twitter.com/rosen_firm或Facebook：https://www.facebook.com/rosenlawfirm/关注我们，了解最新情况。 律师广告。先前的结果并不保证可实现类似结果。 免责声明：本公告之原文版本乃官方授权版本。译文仅供方便了解之用，烦请参照原文，原文版本乃唯一具法律效力之版本。
APYX最後期限提醒：全球頂尖法律事務所ROSEN鼓勵Apyx Medical Corporation投資人在APYX證券集體訴訟的重要截止日期8月5日之前聘請律師
紐約--(BUSINESS WIRE)--(美國商業資訊)--原因：全球投資人權益法律事務所Rosen Law Firm提醒在2021年5月12日至2022年3月11日期間（含上述日期，簡稱「集體訴訟期」）購買Apyx Medical Corporation (NASDAQ: APYX)證券的人士牢記，原告代表的截止日期為2022年8月5日。 這意味著什麼：在集體訴訟期購買了Apyx證券的人士，可能有機會透過勝訴分成安排而獲得賠償，無需支付任何自付費用或成本。 接下來該如何做：如欲加入Apyx集體訴訟，請造訪https://rosenlegal.com/submit-form/?case_id=6835、致電免費電話866-767-3653，或者寄送電子郵件至[email protected]或[email protected]，與Phillip Kim律師聯絡，瞭解有關集體訴訟的更多資訊。法律事務所已經提起了集體訴訟案。如果您希望擔任原告代表，則必須在2022年8月5日之前向法院提出申請。原告代表是代表其他集體成員主導訴訟的代表方。 為什麼選擇ROSEN LAW：我們鼓勵投資人選擇合格且在擔任領導職務方面有成功可查記錄的律師。通常，發佈通知的法律事務所並無可相比的經驗、資源或任何有意義的同儕認可。許多此類法律事務所實際上並不處理證券集體訴訟，而只是充當中間人，把客戶介紹給真正提起訴訟的法律事務所，或與真正提起訴訟的事務所合作。請務必明智選擇法律顧問。Rosen Law Firm在全球為投資人提供服務，專注於證券集體訴訟和股東派生訴訟。Rosen Law Firm曾針對一家中國公司發起了迄今規模最大的證券集體訴訟，並成功達成和解。2017年，Rosen Law Firm曾因其證券集體訴訟和解數量，而被ISS Securities Class Action Services評選為排名第一的法律事務所。自2013年以來，Rosen Law Firm每年都進入該排行榜的前四名，而且已為投資人追回數億美元的資金。事務所僅在2019年便為投資人追回了超過4.38億美元的資金。2020年，創始合夥人Laurence Rosen被law360評選為「最佳原告律師」(Titan of Plaintiffs’ Bar)。事務所的眾多律師都得到Lawdragon和Super Lawyers的表揚。 案件詳情：本訴訟認為，被告在整個集體訴訟期間做出虛假和/或誤導性陳述，和/或未揭露：(1)大量Apyx的Advanced Energy產品被用於說明書之外的適應症；(2)此類未按說明書使用的行為導致Apyx提交的報告嚴重不良事件的醫療器材報告數量增加；(3)因此，Apyx很可能遭受監管部門審查；(4)由於上述原因，Apyx的財務業績將受到不利影響；以及(5)由於上述原因，被告關於Apyx的業務、經營和前景的有利陳述具有重大誤導性和/或缺乏合理依據。訴訟稱，當市場瞭解真實情況後，投資人便蒙受了損失。 如欲加入Apyx集體訴訟，請造訪https://rosenlegal.com/submit-form/?case_id=6835、致電免費電話866-767-3653，或者寄送電子郵件至[email protected]或[email protected]，與Phillip Kim律師聯絡，瞭解有關集體訴訟的更多資訊。 上述訴訟的集體尚未得到認證。在此之前，除受聘之外，律師將不會為個人提供法律服務。個人可自行選擇聘請律師，也可以作為缺席集體訴訟成員，且目前無需採取任何行動。投資人在未來任何可能的賠償中的分成金額與其是否為原告代表無關。 敬請在LinkedIn：https://www.linkedin.com/company/the-rosen-law-firm、Twitter：https://twitter.com/rosen_firm或Facebook：https://www.facebook.com/rosenlawfirm/關注我們，瞭解最新情況。 律師廣告。先前的結果並不保證可獲致類似結果。 免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。
Source: https://incomestatements.info
Category: Stock Reports